PD-L1 生物標記檢測市場 - 全球產業規模、佔有率、趨勢、機會和預測，按癌症類型、檢測試劑盒類型、最終用途、地區和競爭情況細分，2020-2030 年預測

2024 年全球 PD-L1 生物標記檢測市場價值為 7.6431 億美元，預計到 2030 年將達到 12.0651 億美元，複合年成長率為 7.88%。程序性死亡配體 1 (PD-L1) 是一種存在於癌細胞表面的蛋白質，在調節針對癌症的免疫反應中起著關鍵作用。 PD-L1 表現的生物標記檢測在腫瘤學領域已獲得顯著重視，可幫助臨床醫生就免疫療法治療方案做出明智的決定。該市場涵蓋廣泛的診斷測試、技術和服務，旨在評估各種癌症類型中的 PD-L1 表達水平，主要是非小細胞肺癌 (NSCLC)、黑色素瘤、膀胱癌等。

全球 PD-L1 生物標記檢測市場的關鍵促進因素之一是免疫檢查點抑制劑（如 PD-1 和 PD-L1 抑制劑）在治療多種晚期癌症方面取得的顯著成功。生物標記測試有助於識別最有可能從這些免疫療法中受益的患者，從而改善治療結果並減少無反應患者的不必要的副作用。此外，正在進行的研究和臨床試驗繼續擴大 PD-L1 檢測的範圍，涵蓋新的癌症類型和治療環境。

市場特點是擁有大量的檢測方法，包括免疫組織化學 (IHC)、聚合酶鏈反應 (PCR) 和下一代定序 (NGS)，每種方法都有各自的優點和限制。此外，市場在這些測試的採用和可用性方面表現出地理差異，已開發地區在技術採用和基礎設施方面處於領先地位。

隨著精準醫療日益受到重視，PD-L1 生物標記檢測正成為診斷領域不可或缺的一部分，可實現個人化治療策略並改善病患照護。然而，在這個充滿活力的市場中，測試協議標準化、監管障礙和成本效益等挑戰仍然存在。

主要市場促進因素

癌症發生率上升

主要市場挑戰

PD-L1 表現的異質性

主要市場趨勢

個人化醫療

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第4章：全球 PD-L1 生物標記檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依癌症類型（非小細胞肺癌、腎癌、黑色素瘤、頭頸癌、膀胱癌、其他）
  • 依檢測試劑盒類型（PD-L1 22C3 IHC、PD-L1 28-8 IHC、PD-L1 SP263、PD-L1 SP142）
  • 依最終用途（研發、診斷）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按癌症類型
  • 按檢測試劑盒類型
  • 按最終用途
  • 按地區

第 5 章：亞太地區 PD-L1 生物標記檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按癌症類型
  • 按檢測試劑盒類型
  • 按最終用途
  • 按國家
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 6 章：歐洲 PD-L1 生物標記檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 7 章：北美 PD-L1 生物標記檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲 PD-L1 生物標記檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 9 章：中東和非洲 PD-L1 生物標記檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 10 章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 12 章：全球 PD-L1 生物標記檢測市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• AstraZeneca PLC
• Merck Group (SigmaAldrich Co., LLC)
• F. Hoffmann-La Roche Ltd.
• Abcam
• Agilent technologies
• NeoGenomics Laboratories, Inc.
• ACROBiosystems
• PerkinElmer Inc.
• Guardant Health
• Quanterix

第 15 章：策略建議

第16章 關於出版商,免責事項

Global PD-L1 Biomarker Testing Market was valued at USD 764.31 Million in 2024 and is expected to reach USD 1206.51 Million in the forecast period with a CAGR of 7.88% through 2030. The Global PD-L1 Biomarker Testing Market has emerged as a critical component of modern cancer diagnosis and treatment. Programmed Death-Ligand 1 (PD-L1) is a protein found on the surface of cancer cells that plays a pivotal role in regulating the immune response against cancer. Biomarker testing for PD-L1 expression has gained significant prominence in the field of oncology, helping clinicians make informed decisions about immunotherapy treatment options. This market encompasses a wide range of diagnostic tests, technologies, and services aimed at assessing PD-L1 expression levels in various cancer types, primarily non-small cell lung cancer (NSCLC), melanoma, bladder cancer, and others.

One of the key drivers of the Global PD-L1 Biomarker Testing Market is the remarkable success of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, in treating a variety of advanced cancers. Biomarker testing helps identify patients who are most likely to benefit from these immunotherapies, thereby improving treatment outcomes and reducing unnecessary side effects in non-responsive patients. Additionally, ongoing research and clinical trials continue to expand the scope of PD-L1 testing, encompassing new cancer types and treatment settings.

The market is characterized by a plethora of testing methods, including immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS), each offering its own advantages and limitations. Furthermore, the market exhibits geographical variations in terms of adoption and availability of these tests, with developed regions leading the way in terms of technology adoption and infrastructure.

As precision medicine gains prominence, PD-L1 biomarker testing is becoming an integral part of the diagnostic landscape, enabling personalized treatment strategies, and improving patient care. However, challenges such as standardization of testing protocols, regulatory hurdles, and cost-effectiveness remain pertinent in this dynamic market.

Key Market Drivers

Rising Incidence of Cancer

The Global PD-L1 Biomarker Testing Market has been significantly propelled by the rising incidence of cancer worldwide. In 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths globally. This escalating cancer burden underscores the necessity for effective diagnostic and treatment strategies. As the prevalence of various cancer types continues to surge, there is an increasing demand for precise and personalized treatment approaches. PD-L1 biomarker testing has emerged as a crucial tool in this context, enabling healthcare providers to identify the most suitable candidates for immunotherapy.

One of the key factors contributing to the rising cancer incidence is changing lifestyles and environmental factors. Factors such as smoking, poor dietary habits, exposure to environmental toxins, and sedentary lifestyles have contributed to the growing prevalence of cancer. Additionally, an aging population also plays a significant role, as cancer risk tends to increase with age. As the global population continues to age, the burden of cancer is expected to rise, further driving the demand for effective diagnostic tools like PD-L1 testing.

Advancements in medical research have unveiled new insights into the complexity of cancer, revealing that it is not a single disease but rather a diverse collection of diseases with unique genetic profiles. This understanding has led to the development of targeted therapies and immunotherapies, which have shown remarkable success in treating various cancer types. PD-L1 biomarker testing is at the forefront of this revolution, as it helps identify patients who are most likely to respond positively to immunotherapy.

The rising incidence of cancer is a pivotal driver behind the growth of the Global PD-L1 Biomarker Testing Market. As the world grapples with the increasing burden of cancer, the need for precise and effective diagnostic tools has never been greater. PD-L1 testing not only improves treatment outcomes but also represents a significant step towards personalized medicine, where each patient's unique genetic profile informs their treatment plan, ultimately enhancing the chances of successful cancer management.

Key Market Challenges

Heterogeneity of PD-L1 Expression

Tumor heterogeneity makes it challenging to obtain a representative tissue sample for testing. A biopsy from one area of a tumor may yield different results from another, potentially leading to inaccurate assessments of a patient's likelihood to respond to immunotherapy. This inconsistency can result in patients receiving suboptimal treatment or being excluded from potentially beneficial therapies due to misleading test results.

The lack of a standardized approach for PD-L1 biomarker testing exacerbates the issue of heterogeneity. Different pharmaceutical companies and diagnostic manufacturers may use their own proprietary tests and scoring systems, making it challenging to establish uniform criteria for PD-L1 positivity. This lack of standardization can lead to inconsistencies in test results across laboratories and hinder the comparability of data in clinical trials.

The heterogeneous nature of PD-L1 expression adds complexity to treatment decisions. Clinicians must carefully consider the location and extent of PD-L1 expression within a tumor, as well as the potential presence of immune cells in the tumor microenvironment. This complexity can delay treatment initiation and complicate the selection of the most appropriate immunotherapy regimen for individual patients.

In some cases, PD-L1 expressions may be present but go undetected due to sampling limitations. Patients with low or focal PD-L1 expression may be classified as negative, leading to missed opportunities for immunotherapy. Underdiagnosis can negatively impact patient outcomes and limit the effectiveness of immune checkpoint inhibitors.

Key Market Trends

Personalized Medicine

Personalized medicine has emerged as a powerful driver behind the growth of the Global PD-L1 Biomarker Testing Market. This transformative approach to healthcare focuses on tailoring treatments to the individual genetic and molecular characteristics of each patient. Within this paradigm, PD-L1 biomarker testing plays a pivotal role, as it enables clinicians to make highly informed decisions about cancer treatment strategies.

In personalized medicine, the one-size-fits-all approach is replaced with precision. PD-L1 testing allows healthcare providers to assess the specific PD-L1 expression levels in a patient's tumor tissue. This information is crucial because it helps identify whether a patient is likely to respond favorably to immune checkpoint inhibitor therapies, such as PD-1 and PD-L1 inhibitors. By accurately pinpointing potential responders, personalized medicine ensures that patients receive the most suitable and effective therapies, while avoiding unnecessary treatments that may carry risks and side effects without offering benefits.

The rise of personalized medicine has significantly expanded the scope of PD-L1 biomarker testing beyond its initial applications. While it was initially associated primarily with non-small cell lung cancer (NSCLC), its relevance has broadened to encompass a wide range of cancer types, including breast cancer, gastric cancer, and head and neck cancer, among others. This expanded applicability ensures that PD-L1 testing meets the needs of an increasingly diverse patient population.

Key Market Players

• AstraZeneca PLC
• Merck Group (SigmaAldrich Co., LLC)
• F. Hoffmann-La Roche Ltd.
• Abcam
• Agilent technologies
• NeoGenomics Laboratories, Inc.
• ACROBiosystems
• PerkinElmer Inc.
• Guardant Health
• Quanterix

Report Scope:

In this report, the Global PD-L1 Biomarker Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PD-L1 Biomarker Testing Market, By Cancer Type:

• NSCLC
• Kidney Cancer
• Melanoma
• Head and Neck
• Bladder Cancer
• Others

PD-L1 Biomarker Testing Market, By Assay Kit Type:

• PD-L1 22C3 IHC
• PD-L1 28-8 IHC
• PD-L1 SP263
• PD-L1 SP142

PD-L1 Biomarker Testing Market, By End Use:

• Research and Development
• Diagnostics

PD-L1 Biomarker Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PD-L1 Biomarker Testing Market.

Available Customizations:

Global PD-L1 Biomarker Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global PD-L1 Biomarker Testing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others)
  • 4.2.2. By Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142)
  • 4.2.3. By End Use (Research and Development, Diagnostics)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Cancer Type
  • 4.3.2. By Assay Kit Type
  • 4.3.3. By End Use
  • 4.3.4. By Region

5. Asia Pacific PD-L1 Biomarker Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type
  • 5.2.2. By Assay Kit Type
  • 5.2.3. By End Use
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China PD-L1 Biomarker Testing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Cancer Type
      • 5.3.1.2.2. By Assay Kit Type
      • 5.3.1.2.3. By End Use
  • 5.3.2. India PD-L1 Biomarker Testing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Cancer Type
      • 5.3.2.2.2. By Assay Kit Type
      • 5.3.2.2.3. By End Use
  • 5.3.3. Australia PD-L1 Biomarker Testing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Cancer Type
      • 5.3.3.2.2. By Assay Kit Type
      • 5.3.3.2.3. By End Use
  • 5.3.4. Japan PD-L1 Biomarker Testing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Cancer Type
      • 5.3.4.2.2. By Assay Kit Type
      • 5.3.4.2.3. By End Use
  • 5.3.5. South Korea PD-L1 Biomarker Testing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Cancer Type
      • 5.3.5.2.2. By Assay Kit Type
      • 5.3.5.2.3. By End Use

6. Europe PD-L1 Biomarker Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Assay Kit Type
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France PD-L1 Biomarker Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Assay Kit Type
      • 6.3.1.2.3. By End Use
  • 6.3.2. Germany PD-L1 Biomarker Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Assay Kit Type
      • 6.3.2.2.3. By End Use
  • 6.3.3. Spain PD-L1 Biomarker Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Assay Kit Type
      • 6.3.3.2.3. By End Use
  • 6.3.4. Italy PD-L1 Biomarker Testing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Cancer Type
      • 6.3.4.2.2. By Assay Kit Type
      • 6.3.4.2.3. By End Use
  • 6.3.5. United Kingdom PD-L1 Biomarker Testing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Cancer Type
      • 6.3.5.2.2. By Assay Kit Type
      • 6.3.5.2.3. By End Use

7. North America PD-L1 Biomarker Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Assay Kit Type
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States PD-L1 Biomarker Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Assay Kit Type
      • 7.3.1.2.3. By End Use
  • 7.3.2. Mexico PD-L1 Biomarker Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Assay Kit Type
      • 7.3.2.2.3. By End Use
  • 7.3.3. Canada PD-L1 Biomarker Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Assay Kit Type
      • 7.3.3.2.3. By End Use

8. South America PD-L1 Biomarker Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Assay Kit Type
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil PD-L1 Biomarker Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Assay Kit Type
      • 8.3.1.2.3. By End Use
  • 8.3.2. Argentina PD-L1 Biomarker Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Assay Kit Type
      • 8.3.2.2.3. By End Use
  • 8.3.3. Colombia PD-L1 Biomarker Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Assay Kit Type
      • 8.3.3.2.3. By End Use

9. Middle East and Africa PD-L1 Biomarker Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Assay Kit Type
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa PD-L1 Biomarker Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Assay Kit Type
      • 9.3.1.2.3. By End Use
  • 9.3.2. Saudi Arabia PD-L1 Biomarker Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Assay Kit Type
      • 9.3.2.2.3. By End Use
  • 9.3.3. UAE PD-L1 Biomarker Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Assay Kit Type
      • 9.3.3.2.3. By End Use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global PD-L1 Biomarker Testing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. AstraZeneca PLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Merck Group (SigmaAldrich Co., LLC)
• 14.3. F. Hoffmann-La Roche Ltd.
• 14.4. Abcam
• 14.5. Agilent technologies
• 14.6. NeoGenomics Laboratories, Inc.
• 14.7. ACROBiosystems
• 14.8. PerkinElmer Inc.
• 14.9. Guardant Health
• 14.10. Quanterix

15. Strategic Recommendations

16. About Us & Disclaimer